OssDsign Catalyst has been launched and is now ready for sale in the U.S. This marks an important step in the company’s strategy of entering the highly scalable bone graft market with its innovative nanosynthetic bone graft that stimulates the formation of healthy bone tissue.
OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion. This graft is composed of a proprietary nanocrystalline structure that can be implanted into the spine and is then resorbed and replaced by new bone tissue. Data from a recently published preclinical study show that OssDsign Catalyst induced rapid and reliable bone formation and that successful fusion was achieved in 100% of the studied subjects at 26 weeks, compared to 60% in the group where a comparable market-cleared device was used.
OssDsign Catalyst received FDA clearance in 2020 and the addressable market for synthetic bone grafts in spinal surgeries is valued at USD 2.6 billion with an expected CAGR of 7% during 2021–2025.
“We have now completed a major commercial milestone and delivered on our promise to launch OssDsign Catalyst in the U.S. during the second half of 2021. The fact that we already now have managed to scale up production and make the product available for the US market is a great achievement by the entire team at OssDsign. We are confident that OssDsign Catalyst will improve the clinical outcome for many patients,” said Morten Henneveld, CEO, OssDsign.
OssDsign Catalyst has been launched and is now ready for sale in the U.S. This marks an important step in the company’s strategy of entering the highly scalable bone graft market with its innovative nanosynthetic bone graft that stimulates the formation of healthy bone tissue.
OssDsign Catalyst is a synthetic bone graft that stimulates the...
OssDsign Catalyst has been launched and is now ready for sale in the U.S. This marks an important step in the company’s strategy of entering the highly scalable bone graft market with its innovative nanosynthetic bone graft that stimulates the formation of healthy bone tissue.
OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion. This graft is composed of a proprietary nanocrystalline structure that can be implanted into the spine and is then resorbed and replaced by new bone tissue. Data from a recently published preclinical study show that OssDsign Catalyst induced rapid and reliable bone formation and that successful fusion was achieved in 100% of the studied subjects at 26 weeks, compared to 60% in the group where a comparable market-cleared device was used.
OssDsign Catalyst received FDA clearance in 2020 and the addressable market for synthetic bone grafts in spinal surgeries is valued at USD 2.6 billion with an expected CAGR of 7% during 2021–2025.
“We have now completed a major commercial milestone and delivered on our promise to launch OssDsign Catalyst in the U.S. during the second half of 2021. The fact that we already now have managed to scale up production and make the product available for the US market is a great achievement by the entire team at OssDsign. We are confident that OssDsign Catalyst will improve the clinical outcome for many patients,” said Morten Henneveld, CEO, OssDsign.
Copy to clipboard 
